• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型拟多巴胺药物（+）-4-丙基-9-羟基萘并恶嗪（PHNO）治疗帕金森病。

(+)-4-Propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism.

作者信息

Stoessl A J, Mak E, Calne D B

出版信息

Lancet. 1985 Dec 14;2(8468):1330-1. doi: 10.1016/s0140-6736(85)92627-3.

DOI:10.1016/s0140-6736(85)92627-3
PMID:2866388
Abstract

PHNO is a naphthoxazine compound with selective D2 agonist properties and a molecular structure unrelated to the morphine and ergot derivatives that have been used to treat Parkinson's disease. A double-blind, dose-ranging study on 8 patients showed that it is effective in the treatment of parkinsonism; its duration of effect of up to 6 h could make it useful for patients who experience wearing-off reactions with levodopa.

摘要

PHNO是一种具有选择性D2激动剂特性的萘氧嗪化合物，其分子结构与用于治疗帕金森病的吗啡和麦角衍生物无关。一项针对8名患者的双盲、剂量范围研究表明，它在治疗帕金森综合征方面有效；其长达6小时的作用持续时间可能对出现左旋多巴疗效减退反应的患者有用。

相似文献

1
(+)-4-Propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism.新型拟多巴胺药物（+）-4-丙基-9-羟基萘并恶嗪（PHNO）治疗帕金森病。
Lancet. 1985 Dec 14;2(8468):1330-1. doi: 10.1016/s0140-6736(85)92627-3.
2
PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent.PHNO [（+）-4-丙基-9-羟基萘并恶嗪]：一种新型有效的抗帕金森病药物。
Neurology. 1988 Oct;38(10):1541-5. doi: 10.1212/wnl.38.10.1541.
3
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.帕金森病控释型MK-458（PHNO）单药治疗：双盲研究及与卡比多巴/左旋多巴的比较
Clin Neuropharmacol. 1991 Jun;14(3):214-27. doi: 10.1097/00002826-199106000-00004.
4
The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.经皮给药（+）-4-丙基-9-羟基萘并恶嗪（+PHNO）的抗帕金森病作用及药代动力学：初步结果
Mov Disord. 1989;4(2):129-38. doi: 10.1002/mds.870040204.
5
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.（+）-4-丙基-9-羟基萘恶嗪作为帕金森病辅助治疗的疗效。
J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):732-5. doi: 10.1136/jnnp.52.6.732.
6
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.MK 458，一种用于晚期帕金森病的选择性强效D2受体激动剂。
Clin Neuropharmacol. 1988 Jun;11(3):191-200. doi: 10.1097/00002826-198806000-00001.
7
Parkinson's disease: further steps forward.帕金森病：进一步的进展
Gerontology. 1987;33(6):369-73. doi: 10.1159/000212905.
8
Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.帕金森病中经鼻胃管和静脉输注（+）-4-丙基-9-羟基萘恶嗪（PHNO）
J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):102-5. doi: 10.1136/jnnp.53.2.102.
9
Antiparkinsonian activity of a single oral dose of PHNO.单次口服PHNO的抗帕金森病活性。
Mov Disord. 1987;2(1):47-51. doi: 10.1002/mds.870020106.
10
(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.（+）-4-丙基-9-羟基萘并恶嗪在帕金森病中的应用
Lancet. 1986 Apr 19;1(8486):906. doi: 10.1016/s0140-6736(86)91004-4.

引用本文的文献

1
Binding of (+)PHNO and other D2-dopamine agonists to D1-dopamine receptors labelled by [3H]SCH 23390.（+）PHNO及其他D2-多巴胺激动剂与用[3H]SCH 23390标记的D1-多巴胺受体的结合。
J Neural Transm. 1987;69(1-2):147-51. doi: 10.1007/BF01244105.
2
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.（+）-4-丙基-9-羟基萘并恶嗪对用1-甲基-4-苯基-1,2,3,6-四氢吡啶诱发帕金森病的灵长类动物的行为影响。
Naunyn Schmiedebergs Arch Pharmacol. 1988 Jul;338(1):35-8. doi: 10.1007/BF00168809.
3
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
（+）-4-丙基-9-羟基萘恶嗪作为帕金森病辅助治疗的疗效。
J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):732-5. doi: 10.1136/jnnp.52.6.732.
4
Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist.
J Neural Transm. 1989;75(1):11-20. doi: 10.1007/BF01250640.
5
Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）处理的松鼠猴中左旋多巴诱发的运动障碍的特征
Psychopharmacology (Berl). 1990;102(1):21-7. doi: 10.1007/BF02245739.
6
(+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys.（+）-PHNO：一种新型抗帕金森病药物，在经MPTP处理的松鼠猴中不会诱发舞蹈症。
J Neurol Neurosurg Psychiatry. 1990 Jul;53(7):622-3. doi: 10.1136/jnnp.53.7.622.